One in five patients treated with the standard chemotherapy duo for pancreatic cancer develops a rash, and now researchers have pinpointed who is most vulnerable. A retrospective study of 313 patients receiving gemcitabine plus nanoparticle albumin-bound paclitaxel, known as nab-paclitaxel, has identified baseline renal impairment as an independent risk factor for rash and regular co-administration of non-steroidal anti-inflammatory drugs as a surprising protective factor. The findings, published in Supportive Care in Cancer, offer clinicians a practical tool for anticipating skin toxicity during the first cycle of treatment.
Pancreatic cancer remains one of the deadliest malignancies, and the combination of gemcitabine with nab-paclitaxel has become a cornerstone of therapy since trials demonstrated increased survival with the pairing. Yet skin rash is a frequently observed adverse effect of this regimen, and its clinical characteristics have remained poorly understood. Yoshitaka Saito of Hokkaido University of Science and colleagues at Hokkaido University Hospital set out to identify factors associated with rash development in a real-world setting, where patients often have comorbidities and co-medications that clinical trials exclude.
The team retrospectively evaluated 313 patients with pancreatic cancer receiving the combination therapy. The primary endpoint was to identify factors associated with all-grade rash during the first cycle of treatment. The secondary endpoint examined the change in eosinophil levels from baseline to the nearest assessment time point after rash developed in patients who experienced symptoms. The incidence of all-grade rash was 20.4 percent, with grades 1 and 2 accounting for 18.5 percent and 1.9 percent respectively, indicating that most reactions were mild.
Multivariable logistic regression analysis revealed that baseline renal impairment doubled the odds of developing rash, with an adjusted odds ratio of 2.01 and a 95 percent confidence interval of 1.03 to 3.91, reaching statistical significance at P equal to 0.04. In contrast, patients who regularly took NSAIDs alongside their chemotherapy were significantly less likely to develop rash, with an adjusted odds ratio of 0.44 and a confidence interval of 0.20 to 0.91, significant at P equal to 0.03. These results suggest that kidney function and anti-inflammatory co-medication shape the skin’s response to this drug combination.
The renal connection has biological plausibility. Gemcitabine is cleared primarily through the kidneys, and patients with hepatic or renal dysfunction have been shown in pharmacokinetic trials to handle the drug differently. Kidney disease is also associated with a chronic inflammatory state, characterized by elevated pro-inflammatory cytokines such as interleukin-6, which the kidneys and splanchnic organs normally help clear. This inflammatory milieu could sensitize the skin to drug reactions, making patients with impaired renal function more susceptible to rash when exposed to gemcitabine and nab-paclitaxel.
The protective effect of NSAIDs is equally intriguing. Previous studies have suggested that NSAIDs may prevent acneiform skin rashes related to epidermal growth factor receptor inhibitors in lung cancer patients, and celecoxib has been shown to prevent capecitabine-related hand-foot syndrome in colorectal cancer patients. The mechanism likely involves suppression of prostaglandin-mediated inflammation in the skin. Because nab-paclitaxel and gemcitabine can trigger inflammatory cascades that manifest as maculopapular eruptions, regular NSAID exposure may dampen this response before it becomes clinically apparent.
The secondary endpoint added an immunological dimension to the story. Among patients who developed rash, eosinophilia at the nearest time point after symptom onset occurred in 12.5 percent, with eosinophil levels significantly elevated from baseline. Eosinophils are white blood cells typically associated with allergic and immune-mediated reactions, and their rise suggests partial involvement of an immune-mediated mechanism in the rash. This observation aligns with the broader understanding that drug allergies involve complex immune pathways rather than simple toxicity.
The study’s real-world design is both its strength and its limitation. Unlike randomized trials, which enroll carefully selected patients, this retrospective analysis captured the messy reality of clinical practice, where renal impairment, co-medications, and comorbidities coexist. The authors note that the retrospective nature means causality cannot be definitively established, and the single-center design may limit generalizability. Nevertheless, the large sample size and multivariable analysis strengthen the credibility of the identified associations.
For clinicians, the findings carry immediate practical implications. Patients with baseline renal impairment starting gemcitabine plus nab-paclitaxel should be monitored closely for rash during the first cycle, and the presence of regular NSAID use may offer a degree of protection. The study also raises the question of whether prophylactic NSAID administration could be tested prospectively as a rash-prevention strategy, an approach already supported by evidence from other chemotherapy-induced skin toxicities. As pancreatic cancer treatment continues to evolve, understanding the factors that shape adverse reactions becomes as important as understanding the factors that shape survival.
Beyond the headline findings, the study sits within a longer history of dermatological toxicity associated with both of its component drugs. Gemcitabine has been linked to maculopapular eruptions since the 1990s, when early case reports described such rashes in patients with non-small-cell lung cancer receiving the drug. Subsequent reviews of chemotherapeutic agents and the skin catalogued these reactions as among the more common cutaneous adverse events of nucleoside analog therapy, and later Japanese work documented a characteristic distribution of gemcitabine-associated maculopapular rash that clinicians can learn to recognize. Nab-paclitaxel, for its part, carries its own dermatological profile, and meta-analytic comparisons of nanoparticle albumin-bound paclitaxel against conventional solvent-based paclitaxel have quantified the relative skin toxicity of the albumin-bound formulation. The combination regimen therefore stacks two independently rash-prone agents, which helps explain why one in five patients in the Hokkaido cohort was affected.
The pharmacological rationale for the renal impairment finding extends beyond simple drug accumulation. Phase I and pharmacokinetic trials conducted by the Cancer and Leukemia Group B specifically examined gemcitabine in patients with hepatic or renal dysfunction, establishing that clearance of the drug and its metabolites is altered when kidney function declines. Although the label guidance for gemcitabine has historically been cautious about patients with renal compromise, the present study is notable for linking that pharmacokinetic vulnerability to a clinically observable cutaneous outcome rather than to the hematological toxicity more commonly studied in this population. The inflammatory dimension of chronic kidney disease, with its elevated circulating cytokines, offers a complementary explanation: the same patients may be primed for exaggerated inflammatory responses in the skin, independent of drug exposure levels.
The NSAID signal also gains depth from the pharmacological literature. Prophylactic dexamethasone has long been used to prevent severe gemcitabine-associated rash, and the Japanese package insert for nab-paclitaxel reflects established practice around premedication. Against this backdrop, the observation that regular NSAID co-administration roughly halved the odds of rash is consistent with a growing body of evidence that prostaglandin signaling contributes to chemotherapy-induced skin toxicity. Randomized trials of celecoxib and topical diclofenac for capecitabine-related hand-foot syndrome, along with retrospective series suggesting that NSAIDs mitigate epidermal growth factor receptor inhibitor rashes, collectively point toward a shared inflammatory pathway that cutaneous toxicities of diverse anticancer drugs may traverse. The Hokkaido findings extend this hypothesis to a taxane-and-nucleoside-analog combination for which no such preventive strategy had previously been described.
The eosinophil data deserve particular attention because they were collected prospectively in time relative to symptom onset, even though the overall design was retrospective. Eosinophilia developed in only a minority of patients with rash, which the authors interpret as evidence for partial rather than dominant immune mediation. This nuance matters for how the findings are applied. If rash were purely a T-cell mediated drug allergy, one might expect more uniform eosinophil elevation and a stronger case for prophylactic corticosteroids. The mixed picture instead suggests that the reaction may represent a spectrum, with inflammatory and toxic mechanisms operating alongside immune ones, and that different patients may sit at different points on that spectrum.
Pharmacogenomic considerations add another layer that the study could not directly address but that the cited literature frames clearly. Polymorphisms in cytidine deaminase, the enzyme responsible for gemcitabine catabolism, have been shown to influence both the pharmacokinetics of the drug and the toxicity of gemcitabine-based chemotherapy in Japanese populations. On the taxane side, variants in CYP2C8, CYP3A4, CYP3A5, and the transporter ABCB1 have been associated with paclitaxel clearance and with paclitaxel-induced neuropathy. Renal impairment may itself alter the exposure to gemcitabine metabolites, effectively functioning as a clinical surrogate for some of the same variability that pharmacogenomics captures. Future studies combining genetic profiling with renal function assessment could clarify whether the observed risk factor operates through drug exposure, inflammation, or both.
Several methodological caveats shape how strongly the conclusions can be generalized. The single-center design at a Japanese academic hospital means the co-medication patterns, including the prevalence of regular NSAID use, may differ from those in other health systems where over-the-counter NSAID consumption is higher or lower. The restriction of the primary endpoint to rash during the first cycle leaves open the question of whether the same factors govern later-onset eruptions, which are common with gemcitabine and may follow repeated exposure. The grading distribution, with grade 3 or higher reactions essentially absent, means the study speaks to mild toxicity rather than to the severe cutaneous reactions that occasionally prompt drug discontinuation. Prospective validation, ideally with a randomized NSAID prophylaxis arm, would be needed before the protective association could be translated into a clinical recommendation.
Even with those limitations, the study contributes to a broader shift in supportive care thinking, in which the prevention of low-grade but quality-of-life-affecting toxicities is treated as a legitimate research target. Rash may appear trivial next to neutropenia or neuropathy, but it affects patient comfort, adherence, and willingness to continue treatment, and precedent from the EGFR inhibitor field shows that proactive management of skin toxicity can meaningfully improve treatment continuation. Identifying renal impairment as a marker of elevated risk gives oncology teams a simple, routinely available variable to flag at treatment initiation, while the NSAID association provides a testable hypothesis for the next generation of prevention studies in pancreatic cancer supportive care.
Subject of Research: Health
Article Title: Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer
Article References: Saito, Y., Takekuma, Y., Komatsu, Y., & Sugawara, M. (2026). Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer. Supportive Care in Cancer, 34(9), Article 912. https://doi.org/10.1007/s00520-026-11157-0
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11157-0
Keywords: Identification, factors, associated, rash, during, gemcitabine, plus, nanoparticle, albumin-bound, paclitaxel, treatment, pancreatic
News Source: Nathaniel Bowman. (October 17, 2026). Kidney Trouble Doubles Rash Risk During Pancreatic Cancer Drug Combo, Study Finds. Scienmag.
